Genmab A/S (GMAB) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Royalty Pharma (RPRX) has outperformed Genmab A/S (GMAB) over the past year, gaining 56.1% versus a gain of 10.1%. Over five years, RPRX leads with a +46.4% price change compared with -18.9% for GMAB. Royalty Pharma is the larger company by market cap ($32.48 billion vs $22.17 billion), about 1.5 times the size, while Genmab A/S is growing revenue faster (+19.2% vs +5.1%).
On valuation, Royalty Pharma trades at a lower forward P/E (9.8x vs 23.6x for Genmab A/S). Royalty Pharma pays a dividend yielding 1.62%, while Genmab A/S does not currently pay one. Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus 25.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | RPRX |
|---|---|---|
| Share price | $36.05 | $56.21 |
| Market cap | $22.17B | $32.48B |
| 1-day change | -1.64% | -0.97% |
| YTD return | +17.05% | +45.47% |
| 1-year return | +10.11% | +56.05% |
| 5-year return | -18.86% | +46.42% |
| P/E ratio (TTM) | 28.39 | 29.90 |
| Forward P/E | 23.64 | 9.80 |
| EPS (TTM) | $1.27 | $1.88 |
| Dividend yield | 0.00% | 1.62% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | $3.72B | $2.38B |
| Revenue growth (YoY) | +19.19% | +5.06% |
| Net income (latest FY) | $963.00M | $770.95M |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | 65.58% |
| Net margin | 25.89% | 32.42% |
| 52-week high | $40.17 | $64.38 |
| 52-week low | $23.62 | $35.23 |
| Distance from 52-week high | -10.26% | -12.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +19.89% | +16.31% |
| Average volume | 2.83M | 2.92M |
| Shares outstanding | 614.90M | 445.28M |
| Employees | 3,119 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed GMAB by 45.9 percentage points over the past year.
- Royalty Pharma offers a meaningfully higher dividend yield (1.62% vs 0.00%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus 25.9 cents for Genmab A/S.
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs +5.06%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
GMAB vs RPRX FAQ
Which is bigger, Genmab A/S or Royalty Pharma?
Royalty Pharma (RPRX) is larger, with a market capitalization of $32.48B compared with $22.17B for Genmab A/S (GMAB).
Which stock has performed better over the past year, GMAB or RPRX?
RPRX returned +56.05% over the past 12 months, compared with +10.11% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or RPRX?
GMAB has the lower trailing P/E at 28.4, versus 29.9 for RPRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Genmab A/S or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.62%, while Genmab A/S does not currently pay a regular dividend.
Are Genmab A/S and Royalty Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.